These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26560137)

  • 41. Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States.
    Aleppo G; Bode B; Carlson AL
    Clin Diabetes; 2022; 40(4):413-424. PubMed ID: 36381308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Benefits and Limits of Technological Advances in Glucose Management Around Physical Activity in Patients Type 1 Diabetes.
    Tagougui S; Taleb N; Rabasa-Lhoret R
    Front Endocrinol (Lausanne); 2018; 9():818. PubMed ID: 30713524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ultrafast-acting insulins: state of the art.
    Heinemann L; Muchmore DB
    J Diabetes Sci Technol; 2012 Jul; 6(4):728-42. PubMed ID: 22920797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Diabetes Technology: Striving for the Artificial Pancreas.
    Allen N; Gupta A
    Diagnostics (Basel); 2019 Mar; 9(1):. PubMed ID: 30875898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons.
    Renard E
    J Diabetes Sci Technol; 2008 Jul; 2(4):735-8. PubMed ID: 19885254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Insulin pumps].
    Martín Vaquero P; Fernández Martínez A; Pallardo LF
    Med Clin (Barc); 2004 Jun; 123(1):26-30. PubMed ID: 15207225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent Advances in Insulin Therapy.
    Wilson LM; Castle JR
    Diabetes Technol Ther; 2020 Dec; 22(12):929-936. PubMed ID: 32310681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump.
    Vasigh M; Mohammady J; Hopkins R
    Cureus; 2020 Oct; 12(10):e10886. PubMed ID: 33178538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.
    El-Laboudi AH; Oliver N
    Diabetes Ther; 2015 Sep; 6(3):257-72. PubMed ID: 26328536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin Delivery Hardware: Pumps and Pens.
    Lal R; Leelarathna L
    Diabetes Technol Ther; 2022 Mar; 24(S1):S21-S34. PubMed ID: 35475688
    [No Abstract]   [Full Text] [Related]  

  • 51. Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons.
    Thabit H; Hovorka R
    Expert Opin Drug Deliv; 2016; 13(3):389-400. PubMed ID: 26618219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes: A 24-Hour Randomized Controlled Crossover Study.
    Reddy M; Herrero P; Sharkawy ME; Pesl P; Jugnee N; Pavitt D; Godsland IF; Alberti G; Toumazou C; Johnston DG; Georgiou P; Oliver NS
    J Diabetes Sci Technol; 2015 Nov; 10(2):405-13. PubMed ID: 26581881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.
    Atkin S; Javed Z; Fulcher G
    Ther Adv Chronic Dis; 2015 Nov; 6(6):375-88. PubMed ID: 26568812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Valuing technology: A qualitative interview study with physicians about insulin pump therapy for children with type 1 diabetes.
    Shulman R; Miller FA; Daneman D; Guttmann A
    Health Policy; 2016 Jan; 120(1):64-71. PubMed ID: 26563632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.
    Freemantle N; Mamdani M; Vilsbøll T; Kongsø JH; Kvist K; Bain SC
    Diabetes Ther; 2015 Dec; 6(4):573-591. PubMed ID: 26582052
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence.
    Kaiserman K; Jung H; Benabbad I; Karges B; Polak M; Rosilio M
    Pediatr Diabetes; 2017 Mar; 18(2):81-94. PubMed ID: 27390032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coming of age: the artificial pancreas for type 1 diabetes.
    Thabit H; Hovorka R
    Diabetologia; 2016 Sep; 59(9):1795-805. PubMed ID: 27364997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.